RhPDGF-BB
Phase 2Small molecule
RhPDGF-BB is one of 77 small molecule programs targeting Anal fistula. It is currently in Phase 2.
3
Indications
4
Total Trials
2
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
210 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaPhase 3
Zyvox
PfizerPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Tygacil
PPrism Pharmaceuticals
Phase 3
Cubicin
BBaxter Healthcare Corporation
Phase 3
Urokinase
Mmedac GmbH
Phase 3
Bemiparin
RRovi Pharmaceuticals Laboratories
Phase 3
Biochaperone Combo
AAdocia
Phase 3
Beta-Glucan
BBiotec Pharmacon ASA
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lateral Epicondylitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RhPDGF-BB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- LLynch Biologics LLC